Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jan 14;19(1):68.
doi: 10.1186/s12885-019-5266-4.

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Houda Bahig  1   2 , Francine Aubin  3   2 , John Stagg  2 , Olguta Gologan  2   4 , Olivier Ballivy  1   2 , Eric Bissada  2   5 , Felix-Phuc Nguyen-Tan  1   2 , Denis Soulières  3   2 , Louis Guertin  2   5 , Edith Filion  1   2 , Apostolos Christopoulos  2   5 , Louise Lambert  1   2 , Mustapha Tehfe  3   2 , Tareck Ayad  2   5 , Danielle Charpentier  3   2 , Rahima Jamal  3   2 , Philip Wong  6   7
Affiliations
Clinical Trial

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Houda Bahig et al. BMC Cancer. .

Abstract

Background: The efficacy of immunotherapy targeting the PD-1/PD-L1 pathway has previously been demonstrated in metastatic head and neck squamous cell carcinoma (HNSCC). Stereotactic Body Radiotherapy (SBRT) aims at ablating metastatic lesions and may play a synergistic role with immunotherapy. The purpose of this study is to assess the safety and efficacy of triple treatment combination (TTC) consisting of the administration of durvalumab and tremelimumab in combination with SBRT in metastatic HNSCC.

Method: This is a phase I/II single arm study that will include 35 patients with 2-10 extracranial metastatic lesions. Patients will receive durvalumab (1500 mg IV every 4 weeks (Q4W)) and tremelimumab (75 mg IV Q4W for a total of 4 doses) until progression, unacceptable toxicity or patient withdrawal. SBRT to 2-5 metastases will be administered between cycles 2 and 3 of immunotherapy. The safety of the treatment combination will be evaluated through assessment of TTC-related toxicities, defined as grade 3-5 toxicities based on Common Terminology Criteria for Adverse Events (v 4.03), occurring within 6 weeks from SBRT start, and that are definitely, probably or possibly related to the combination of all treatments. We hypothesize that dual targeting of PD-L1 and CTLA-4 pathways combined with SBRT will lead to < 35% grade 3-5 acute toxicities related to TTC. Progression free survival (PFS) will be the primary endpoint of the phase II portion of this study and will be assessed with radiological exams every 8 weeks using the RECIST version 1.1 criteria.

Discussion: The combination of synergistic dual checkpoints inhibition along with ablative radiation may significantly potentiate the local and systemic disease control. This study constitutes the first clinical trial combining effects of SBRT with dual checkpoint blockade with durvalumab and tremelimumab in the treatment of metastatic HNSCC. If positive, this study would lead to a phase III trial testing this treatment combination against standard of care in metastatic HNSCC.

Trial registration: NCT03283605 . Registration date: September 14, 2017; version 1.

Keywords: Durvalumab; Head and neck cancer; Immunotherapy; Metastatic; SBRT; Tremelimumab.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The proposed study has been approved by the Centre Hospitalier de l’Université de Montreal IRB.

Consent for publication

Not applicable.

Competing interests

None.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Study schema. HNSCC = head and neck squamous cell carcinoma; SBRT = stereotactic body radiotherapy; PFS = Progression free survival; LC = local control; OS = overall survival
Fig. 2
Fig. 2
Durvalumab (MEDI4736) and tremelimumab administration schedule
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi: 10.3322/caac.21332. - DOI - PubMed
    1. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer. 1993;71(2):452–456. doi: 10.1002/1097-0142(19930115)71:2<452::AID-CNCR2820710228>3.0.CO;2-B. - DOI - PubMed
    1. Ferlito A, Shaha AR, Silver CE, Rinaldo A, Mondin V. Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63(4):202–207. doi: 10.1159/000055740. - DOI - PubMed
    1. Leon X, Quer M, Orus C, del Prado VM, Lopez M. Distant metastases in head and neck cancer patients who achieved loco-regional control. Head neck. 2000;22(7):680–686. doi: 10.1002/1097-0347(200010)22:7<680::AID-HED7>3.0.CO;2-J. - DOI - PubMed
    1. Dragovic AF, Caudell JJ, Spencer SA, Carroll WR, Nabell LA, Bonner JA. Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancer. Head Neck. 2013;35(3):381–387. doi: 10.1002/hed.22977. - DOI - PubMed

Publication types

MeSH terms

Associated data